Financial Statements

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC (ADAP)

$4.85
0.05 (+1.04%)
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in millions

Retained Earning Schedule

Year 2019 2018 2017 2016 2015 2014 2013
Retained Earnings (Previous Year) -318-232-161-90-32-18-
Net Income -137-96-70-72-23--
Stock Dividends -9---35-15-18
Dividend Paid -------
Retained Earnings -456-318-232-161-90-32-18

PPE Schedule

Year 2019 2018 2017 2016 2015 2014 2013
Gross PPE 3641281310-
Annual Depreciation 19038272230
Capital Expenditure -3-5-25-13-10-1-0
Net PPE 523641281310

Intangible and Goodwill Schedule

Year 2019 2018 2017 2016 2015 2014 2013
Intangible and Goodwill (Previous Year) ---0111
New Purchases -----153-151-27
Intangible and Goodwill --01112

Adaptimmune Therapeutics PLC income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Adaptimmune Therapeutics PLC FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.